Merck & Co., Inc.
13F Reported Value
ⓘ$349.4M
Holdings
14
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Merck & Co., Inc. disclosed 14 positions worth $349.4M in its Form 13F-HR for Q1 2026, led by $MRNA (Moderna, Inc.) at 33.6% of the equity portfolio, followed by $PSNL and $KYMR. During the quarter the fund opened 2 new positions and exited 0 — including a new stake in $EIKN. The portfolio is most concentrated in Healthcare (98.7% of disclosed assets). All figures are sourced directly from Merck & Co., Inc.’s Form 13F-HR filing with the SEC under CIK 310158.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 15.9#2,743
Quality
$117.3M2,308,190 sh - 15.7#2,744
Quality
$89.5M14,044,943 sh - 29.2#2,418
Quality
$64.3M772,165 sh - 8.5
Quality
$22.0M1,739,768 sh - —
Quality
$17.6M1,666,666 sh - —
Quality
$17.0M952,844 sh - 8.9
Quality
$7.6M3,545,719 sh - 30.1
Quality
$6.8M272,351 sh EVAXION BIOTECH A/S
—Quality
$4.5M1,214,126 sh- 30.5
Quality
$1.8M93,414 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Moderna, Inc.$MRNA | 15.9#2,743 | $117.3M | 2,308,190 |
 Personalis, Inc.$PSNL | 15.7#2,744 | $89.5M | 14,044,943 |
 Kymera Therapeutics, Inc.$KYMR | 29.2#2,418 | $64.3M | 772,165 |
 Entrada Therapeutics, Inc.$TRDA | 8.5 | $22.0M | 1,739,768 |
 Eikon Therapeutics, Inc.$EIKN | — | $17.6M | 1,666,666 |
 Aktis Oncology, Inc.$AKTS | — | $17.0M | 952,844 |
 Alector, Inc.$ALEC | 8.9 | $7.6M | 3,545,719 |
 SUTRO BIOPHARMA, INC.$STRO | 30.1 | $6.8M | 272,351 |
| EVAXION BIOTECH A/S | — | $4.5M | 1,214,126 |
 Viridian Therapeutics, Inc.\DE$VRDN | 30.5 | $1.8M | 93,414 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Merck & Co., Inc.'s 14 positions.
Showing top 10 of 14 holdings.
Sector Allocation
Healthcare
$344.9M
Other
$4.6M
Full Holdings — Merck & Co., Inc. (Q1 2026)
All 14 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $MRNA | Moderna, Inc. | $117.3M | 33.6% | +0% | 15.9 |
| 2 | $PSNL | Personalis, Inc. | $89.5M | 25.6% | +0% | 15.7 |
| 3 | $KYMR | Kymera Therapeutics, Inc. | $64.3M | 18.4% | +0% | 29.2 |
| 4 | $TRDA | Entrada Therapeutics, Inc. | $22.0M | 6.3% | +0% | 8.5 |
| 5 | $EIKN | Eikon Therapeutics, Inc. | $17.6M | 5.0% | NEW | — |
| 6 | $AKTS | Aktis Oncology, Inc. | $17.0M | 4.9% | NEW | — |
| 7 | $ALEC | Alector, Inc. | $7.6M | 2.2% | +0% | 8.9 |
| 8 | $STRO | SUTRO BIOPHARMA, INC. | $6.8M | 1.9% | +0% | 30.1 |
| 9 | — | EVAXION BIOTECH A/S | $4.5M | 1.3% | +0% | — |
| 10 | $VRDN | Viridian Therapeutics, Inc.\DE | $1.8M | 0.5% | +0% | 30.5 |
| 11 |  $XLO | Xilio Therapeutics, Inc. | $891,309 | 0.3% | -93% | 26.9 |
| 12 | — | CARISMA THERAPEUTICS INC | $47,880 | 0.0% | +0% | — |
| 13 |  $NEUP | Neuphoria Therapeutics Inc. | $40,810 | 0.0% | +0% | — |
| 14 |  $HURA | TuHURA Biosciences, Inc./NV | $34,807 | 0.0% | +39% | — |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Merck & Co., Inc. including:
Track Merck & Co., Inc.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Merck & Co., Inc. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Merck & Co., Inc.
13F Pro is an AI hedge fund tracker and stock research platform. For Merck & Co., Inc. (SEC CIK: 310158), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Merck & Co., Inc.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.